title: Recombinant human bone morphogenetic protein-2 for peri-implant bone regeneration: a case report.
abstract: BACKGROUND
  Currently, clinicians have a limited treatment arsenal in the repair of peri-implant defects. The aim of the present report is to present the clinical results of treating a dental implant using recombinant human bone morphogenetic protein (rhBMP)-2 in an elderly patient.
  
  
  METHODS
  A 75-year-old man presented for routine dental prophylaxis. Clinical and radiographic examination revealed significant loss of attachment and bone loss around an implant replacing the maxillary left first molar. The patient did not report any symptoms, and the implant showed no signs of mobility. Because of the severity of the defect, regenerative treatment using a combination of rhBMP-2 and freeze-dried bone allograft was used.
  
  
  RESULTS
  The patient was followed for 80 weeks postoperatively. By 28 weeks, significant probing depth reduction and radiographic bone fill was observed, and the original implant crown was replaced. From 28 weeks postoperatively to 80 weeks, no significant clinical or radiographic changes were observed.
  
  
  CONCLUSIONS
  rhBMP-2 represents a potential therapeutic modality for severe peri-implant hard tissue loss. Future studies should examine parameters, such as surgical technique, to maximize the rhBMP-2-driven regenerative outcomes.
authors.affiliation: Division of Periodontology, College of Dentistry, The Ohio State University, Columbus, OH 43210, USA.
authors.forename: Shaun A
authors.initials: SA
authors.lastname: Rotenberg
authors.forename: Dimitris N
authors.initials: DN
authors.lastname: Tatakis
mesh_terms: D000368:Aged; D016301:Alveolar Bone Loss / Q000188:drug therapy* / Q000209:etiology; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage / Q000502:physiology*; D001861:Bone Regeneration / Q000187:drug effects / Q000502:physiology*; D019250:Dental Implants, Single-Tooth / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008437:Maxilla; D017622:Periodontal Attachment Loss / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000008:administration & dosage; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000502:physiology*; D016896:Treatment Outcome
chemical_list: D055396:Bone Morphogenetic Protein 2; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2